Pharma Intelligence відкриті
[search 0]
більше

Download the App!

show episodes
 
Deep Pharma Intelligence (DPI) is a leading strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, BioTech, and Healthcare Tech industries. DPI is producing regular analytical reports on major areas of high-potential in the pharmaceutical and healthcare industries, maintaining ratings of companies and governments based on their innovation potential and business activity in the BioTech space, and providing strategic consulting and investment intell ...
 
Loading …
show series
 
Pink Sheet reporters and editor discuss the new monkeypox vaccine EUA, the potential impact of drug pricing legislation, and how things may have been different if the FDA already had a desired technology upgrade.Informa
 
유한양행이 글로벌 제약사로 성장하기 위해 선택한 오픈이노베이션 전략과 R&D 전략에 대해 유한양행의 중앙연구소장이신 오세웅 전무님을 인터뷰한 Scrip기사를 요약한 내용입니다.https://scrip.pharmaintelligence.informa.com/SC146768/No-Future-Without-New-Drugs-Yuhan-CSO-On-Open-Innovation-StrategyKorean-language podcast summarising a recent article from Scrip.Informa
 
In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.Medtech Insight articles addressing topics discussed in this episode:Medtec…
 
In this episode, HBW Insight talks to Mihai Inceu about the challenges of innovating in Europe’s thriving food supplements market. Senior Regulatory Affairs Officer at Jensen R+, Inceu highlights some of the issue companies face in putting new wellness products onto the European market, particularly if they want to make health claims for herbal ing…
 
: 世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。A Japanese-language summary of selected content from Scrip and Pink Sheet, one story at a time.今回取り上げた記事はこちらThe article for this episode is: MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster(邦題意訳「アジアの医療現場で躍進 コ…
 
Pink Sheet reporter looks at the biggest US FDA and pharma industry stories of the week, including the status of US FDA user fee renewal legislation, new real-time oncology review program guidance, Biogen’s ALS accelerated approval play, and Teva settling opioid litigation.Informa
 
Gennova Biopharma’s founder CEO Sanjay Singh talks to Scrip on developing the first Indian and the world’s third mRNA vaccine against COVID-19, following Moderna and Pfizer. After a couple of years in the US at The National Institutes of Health, he returned to set up the company, which is looking at using the technology against cancer and infectiou…
 
In this episode, I speak to Adam Ricciardone, global head of self-care research and development at Johnson & Johnson Consumer Health. Adam identifies four macro trends the company is observing worldwide: total wellness, sustainability, a focus demographic shifts and the “techceleration” of self-care. International Self Care Day was last weekend on …
 
Pink Sheet reporter and editors discuss another project to improve clinical trial diversity in the US, the Patent Trial and Appeal Board director review process, and the FDA promoting its head of controlled substance policy to deputy CDER director.Informa
 
DCTs: Exploring The Innovative Technologies, Push For Diversity, Cybersecurity, And the Future Of Remote TrialsWhile diversity is largely recommended by regulators today, it is quickly becoming apparent diversity is vital for successful clinical trials in the future. For sponsors to fulfil the requirements, continual exploration and use of decentra…
 
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?…
 
바이오텍 가치하락, 바이오신약의 특허 만료 등 시장상황의 변화로 글로벌 제약바이오 업계가 새로운 인수합병 파도에 휩쓸릴 수 있다는 Scrip Intelligence 기사를 요약한 내용입니다.https://scrip.pharmaintelligence.informa.com/SC146589/Are-Market-Conditions-Setting-Up-A-Biopharma-MA-WaveInforma
 
Articles mentioned in this podcast: US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive ApplicationAllowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTCOTC Switch For Daily Oral Contraceptive Brandished In Senate Health Care Policy DuelBarriers To US OTC Emergency Contraceptive Sale…
 
Pink Sheet reporters and editors discuss the FDA’s latest COVID-19 vaccine emergency use authorization, activities during the FDA commissioner’s remaining time in office, and patients requesting a gene therapy risk management plan.Informa
 
In this month’s Digital Health roundup, Medtech Insight’s Barnaby Pickering discusses DeHealth, which developed a platform built on cryptocurrency, and executive interviews with Glooko and Omada Health about their diabetes platforms. Marion Webb will highlight a conversation with Nixon Gwilt Law attorney Bethany Corbin about key steps developers of…
 
Pink Sheet reporters and editors discuss new changes to the Senate drug pricing bill, the FDA’s decision to call a second advisory committee meeting for Amylyx’s ALS drug, and Covis’ request to skip a vote during the hearing on Makena’s withdrawal.Informa
 
欢迎来Citeline中国生物制药热点博客做客!分析热点,政策解读和行业热门追踪是我们的宗旨。在首期的节目中,中国主编杨宏新Brian和资深记者严洁Dexter首先讨论了康方生物最新获得药监局批准,世界首个双特异抗体卡度尼丁单抗Cadonilimab,治疗宫颈癌(https://scrip.pharmaintelligence.informa.com/SC146649/China-Approves-Worlds-First-Bispecific-IO-Drug-Amid-PD-1L1-Glut)。这个获批也是中国第一个批准治疗宫颈癌的肿瘤免疫治疗。默克的K药比较,这个获批有什么意义?对于其他在研的双特异抗体PD-1来说有什么影响?接下来的话题是最近国家药监局公布《关于进一步加强外资企业服务工…
 
Loading …

Короткий довідник

Google login Twitter login Classic login